MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis - PubMed
6 hours ago
- #immunotherapy
- #CAR macrophages
- #brain metastasis
- Brain metastasis affects up to 30% of patients with lung, melanoma, and breast cancers, with a median survival of less than a year.
- Current treatments are limited due to the blood-brain barrier (BBB) blocking most drugs and immunotherapies.
- Researchers engineered macrophages with a chimeric antigen receptor (CAR) targeting mesothelin (MSLN) to combat brain metastasis.
- These CAR macrophages (CARMA) fused with MyD88 can cross the BBB and reduce tumor growth in humanized mouse models.
- CARMA exhibits antigen-specific phagocytosis and a bystander effect by releasing TNF to attack nearby tumor cells lacking the target antigen.
- CARMA shows potential as a novel therapy for brain metastasis, overcoming limitations of current treatments.